Keep adding and if it goes down average down. This is a keeper and at these prices it's a slam dunk. The risk in biotechs is before approval. The company has the only reasonable and easy option in this space. Earnings in one year will put the SP in the $20+ range.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.